A Phase 1B, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Crizotinib (PF-02341066) Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2011
At a glance
- Drugs Axitinib; Bevacizumab; Crizotinib; Sorafenib; Sorafenib; Sunitinib
- Indications Glioblastoma; Liver cancer; Renal cancer; Solid tumours
- Focus Adverse reactions
- 19 Dec 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 18 Oct 2011 Planned end date changed from 1 Oct 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 29 Sep 2011 New trial record